Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GRIN2B 2904 AZD8108 CHEMBL3707355 antagonist ChemblInteractions
GRIN2B 2904 (D)-SERINE CHEMBL285123 agonist GuideToPharmacologyInteractions
GRIN2B 2904 ASPARTIC ACID CHEMBL274323 agonist GuideToPharmacologyInteractions
GRIN2B 2904 CONANTOKIN G CHEMBL525025 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL22304 CHEMBL22304 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 MODAFINIL CHEMBL1373 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 DIZOCILPINE CHEMBL284237 channel blocker GuideToPharmacologyInteractions
GRIN2B 2904 MAGNESIUM CHEMBL2146125 channel blocker GuideToPharmacologyInteractions
GRIN2B 2904 NRX-1074 CHEMBL3545230 partial agonist ChemblInteractions
GRIN2B 2904 ACAMPROSATE CALCIUM CHEMBL2068724 antagonist ChemblInteractions
GRIN2B 2904 KETAMINE HYDROCHLORIDE CHEMBL1714 ChemblInteractions
GRIN2B 2904 CERC-301 CHEMBL2068839 antagonist ChemblInteractions
GRIN2B 2904 ESKETAMINE HYDROCHLORIDE CHEMBL2364609 ChemblInteractions
GRIN2B 2904 L-GLUTAMATE CHEMBL575060 DrugBank 17229973, 17662248
GRIN2B 2904 FELBAMATE CHEMBL1094 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 11752352, 10690753, 18253065, 18311896, 10215667
GRIN2B 2904 N-METHYL-D-ASPARTIC ACID (NMDA) CHEMBL291278 agonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL50267 CHEMBL50267 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CGP-37849 CHEMBL29811 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 AV-101 CHEMBL3545351 antagonist ChemblInteractions
GRIN2B 2904 RALFINAMIDE CHEMBL2107771 antagonist ChemblInteractions
GRIN2B 2904 ESKETAMINE CHEMBL395091 ChemblInteractions
GRIN2B 2904 LATREPIRDINE CHEMBL589390 TdgClinicalTrial
GRIN2B 2904 EVT-101 (CHEMBL3545349) CHEMBL3545349 antagonist TdgClinicalTrial, ChemblInteractions, TTD
GRIN2B 2904 NERAMEXANE MESYLATE CHEMBL2106798 antagonist ChemblInteractions
GRIN2B 2904 CHEMBL140784 CHEMBL140784 agonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL287327 CHEMBL287327 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL31741 CHEMBL31741 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL173031 CHEMBL173031 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL273636 CHEMBL273636 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 SELFOTEL CHEMBL39664 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 KETAMINE CHEMBL742 channel blocker GuideToPharmacologyInteractions
GRIN2B 2904 TENOCYCLIDINE CHEMBL279676 antagonist DrugBank 2538766
GRIN2B 2904 BESONPRODIL CHEMBL219631 antagonist TTD
GRIN2B 2904 MEMANTINE CHEMBL807 TdgClinicalTrial, TEND
GRIN2B 2904 CHEMBL334533 CHEMBL334533 TdgClinicalTrial
GRIN2B 2904 DIMIRACETAM CHEMBL337612 TdgClinicalTrial
GRIN2B 2904 DELUCEMINE CHEMBL2110814 antagonist ChemblInteractions
GRIN2B 2904 LANICEMINE CHEMBL2107647 blocker TdgClinicalTrial, ChemblInteractions
GRIN2B 2904 ORPHENADRINE CITRATE CHEMBL1200395 antagonist ChemblInteractions
GRIN2B 2904 NERAMEXANE CHEMBL2110954 TdgClinicalTrial
GRIN2B 2904 CNS-5161 CHEMBL41306 blocker TdgClinicalTrial, ChemblInteractions
GRIN2B 2904 D-ASPARTATE CHEMBL29757 agonist GuideToPharmacologyInteractions
GRIN2B 2904 GLYCINE CHEMBL773 agonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL280828 CHEMBL280828 agonist GuideToPharmacologyInteractions
GRIN2B 2904 MESORIDAZINE CHEMBL1088 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 CHEMBL191838 CHEMBL191838 antagonist GuideToPharmacologyInteractions
GRIN2B 2904 AMANTADINE HYDROCHLORIDE CHEMBL1569 antagonist, channel blocker GuideToPharmacologyInteractions, ChemblInteractions
GRIN2B 2904 CHEMBL1184349 CHEMBL1184349 channel blocker GuideToPharmacologyInteractions
GRIN2B 2904 PHENCYCLIDINE CHEMBL275528 channel blocker GuideToPharmacologyInteractions
GRIN2B 2904 RAPASTINEL CHEMBL3544917 partial agonist ChemblInteractions
GRIN2B 2904 NEBOGLAMINE CHEMBL1255840 positive allosteric modulator ChemblInteractions
GRIN2B 2904 TRAXOPRODIL CHEMBL17350 antagonist ChemblInteractions, TTD
GRIN2B 2904 Radiprodil CHEMBL182066 antagonist ChemblInteractions, TTD
GRIN2B 2904 MEMANTINE HYDROCHLORIDE CHEMBL1699 ChemblInteractions
GRIN2B 2904 Indantadol CHEMBL3707400 antagonist TdgClinicalTrial, ChemblInteractions
GRIN2B 2904 VALPROIC ACID CHEMBL109 PharmGKB
GRIN2B 2904 ORPHENADRINE (CHLORIDE) CHEMBL1201023 antagonist ChemblInteractions
GRIN2B 2904 GW468816 CHEMBL1207366 antagonist ChemblInteractions
GRIN2B 2904 IFENPRODIL CHEMBL305187 antagonist DrugBank 3365283
GRIN2B 2904 ACETYLCYSTEINE CHEMBL600 activator DrugBank 12183209

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GRIN2B rs2284411 CC methylphenidate efficacy yes These data combine an 8-week open label trial with a 2-year clinical trial prospective study. Efficacy was evaluated as change in symptom severity compared to the baseline using the Korean version of the ADHD rating scale-IV (ADHD-RS). Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT. 27624150 1448262073
GRIN2B rs1019385 AC valproic acid "dosage","metabolism/PK" yes Variant described as GRIN2B -200T>G (rsID not reported). Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA. 21806385 827812721
GRIN2B rs890 A lithium efficacy not stated This is from a review article which does not give all the details. It says that no association was found between the SNP and lithium response, but it does not state exactly how the alleles were compared. Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele C. 21047205 699639262
GRIN2B rs1019385 CC valproic acid "dosage","metabolism/PK" yes and associated with significantly increased InCDR (serum concentration to dose ratio) compared to AA. Variant described as GRIN2B -200T>G (rsID not reported). Genotype CC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC. 21806385 827812715
GRIN2B rs1072388 AA + AG clozapine efficacy no Patients with schizophrenia that is resistant or intolerant to treatment. Genotypes AA + AG are associated with increased response to clozapine in people with Schizophrenia as compared to genotype GG. 26876050 1447945779
GRIN2B rs2058878 A acamprosate efficacy yes Tag SNPs (518 total) were selected within genes associated with alcoholism as well as genes encoding enzymes involved in glycine metabolism, glycine transporters, subunits of glycine receptors, NMDA receptors, genes involved in glutamate reuptake, synthesis or degradation and genes with reported associations with acamprosate treatment outcomes in human or animal studies. The length of time to first alcohol use “survival analysis method” was used to examine associations between clinical variables and genetic markers with efficacy of acomprasate (its ability to length the duration of abstinence from alcohol). The analyses were replicated in a subset of 110 participants from PREDICT, a double-blind randomized controlled trial that compared treatment outcomes including length of abstinence among alcohol- dependent subjects of German descent recruited from inpatient facilities and treated with acamprosate, naltrexone or placebo for 3 months. The strongest association finding, was for the A allele at rs2058878 A allele, which remained significantly associated with longer abstinence even after Bonferroni correction for the number of SNPs included in the analyses (P = 4.6 × 10 - 5, corrected P = 0.024). Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T. 25290263 1184988627
GRIN2B rs2160733 C acamprosate efficacy no Tag SNPs (518 total) were selected within genes associated with alcoholism as well as genes encoding enzymes involved in glycine metabolism, glycine transporters, subunits of glycine receptors, NMDA receptors, genes involved in glutamate reuptake, synthesis or degradation and genes with reported associations with acamprosate treatment outcomes in human or animal studies. The length of time to first alcohol use “survival analysis method” was used to examine associations between clinical variables and genetic markers with efficacy of acomprasate (its ability to length the duration of abstinence from alcohol). The analyses were replicated in a subset of 110 participants from PREDICT, a double-blind randomized controlled trial that compared treatment outcomes including length of abstinence among alcohol- dependent subjects of German descent recruited from inpatient facilities and treated with acamprosate, naltrexone or placebo for 3 months. Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele A. 25290263 1184988665
GRIN2B rs2160734 C acamprosate efficacy no Tag SNPs (518 total) were selected within genes associated with alcoholism as well as genes encoding enzymes involved in glycine metabolism, glycine transporters, subunits of glycine receptors, NMDA receptors, genes involved in glutamate reuptake, synthesis or degradation and genes with reported associations with acamprosate treatment outcomes in human or animal studies. The length of time to first alcohol use “survival analysis method” was used to examine associations between clinical variables and genetic markers with efficacy of acomprasate (its ability to length the duration of abstinence from alcohol). The analyses were replicated in a subset of 110 participants from PREDICT, a double-blind randomized controlled trial that compared treatment outcomes including length of abstinence among alcohol- dependent subjects of German descent recruited from inpatient facilities and treated with acamprosate, naltrexone or placebo for 3 months. Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele T. 25290263 1184988683